title: Tighter Control by Chymotrypsin C (CTRC) Explains Lack of Association between Human Anionic Trypsinogen and Hereditary Pancreatitis.
abstract: The human pancreas expresses two major trypsinogen isoforms, cationic trypsinogen (PRSS1) and anionic trypsinogen (PRSS2). Mutations in PRSS1 cause hereditary pancreatitis by altering cleavage of regulatory nick sites by chymotrypsin C (CTRC) resulting in reduced trypsinogen degradation and increased autoactivation. Despite 90% identity with PRSS1 and a strong propensity for autoactivation, mutations in PRSS2 are not found in hereditary pancreatitis suggesting that activation of this isoform is more tightly regulated. Here, we demonstrated that CTRC promoted degradation and thereby markedly suppressed autoactivation of human anionic trypsinogen more effectively than previously observed with cationic trypsinogen. Increased sensitivity of anionic trypsinogen to CTRC-mediated degradation was due to an additional cleavage site at Leu-148 in the autolysis loop and the lack of the conserved Cys-139-Cys-206 disulfide bond. Significant stabilization of anionic trypsinogen against degradation was achieved by simultaneous mutations of CTRC cleavage sites Leu-81 and Leu-148, autolytic cleavage site Arg-122, and restoration of the missing disulfide bridge. This stands in stark contrast to cationic trypsinogen where single mutations of either Leu-81 or Arg-122 resulted in almost complete resistance to CTRC-mediated degradation. Finally, processing of the trypsinogen activation peptide at Phe-18 by CTRC inhibited autoactivation of anionic trypsinogen, although cationic trypsinogen was strongly stimulated. Taken together, the observations indicate that human anionic trypsinogen is controlled by CTRC in a manner that individual natural mutations are unlikely to increase stability enough to promote intra-pancreatic activation. This unique biochemical property of anionic trypsinogen explains the lack of association of PRSS2 mutations with hereditary pancreatitis.
authors.affiliation: From the Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts 02118.
authors.forename: Zsanett
authors.initials: Z
authors.lastname: Jancsó
authors.affiliation: From the Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts 02118 miklos@bu.edu.
authors.forename: Miklós
authors.identifier: 0000-0003-4513-9922
authors.initials: M
authors.lastname: Sahin-Tóth
mesh_terms: D002918:Chymotrypsin / Q000737:chemistry* / Q000502:physiology; D003553:Cystine / Q000737:chemistry; D004789:Enzyme Activation; D004795:Enzyme Stability; D006801:Humans; D020125:Mutation, Missense; D010195:Pancreatitis / Q000201:enzymology* / Q000235:genetics; D011499:Protein Processing, Post-Translational; D059748:Proteolysis; D014357:Trypsin / Q000737:chemistry* / Q000235:genetics; D014362:Trypsinogen / Q000737:chemistry* / Q000235:genetics
chemical_list: C064831:PRSS2 protein, human; D003553:Cystine; D014362:Trypsinogen; D002918:Chymotrypsin; C117569:chymotrypsin C; D014357:Trypsin
keywords: chymotrypsin; chymotrypsin C; pancreas; serine protease; trypsin; trypsinogen